Twist Bioscience Signs Two Biopharma Technology Agreements to Enable Novel Therapeutics Discovery

Biopharma

Home » Health and medicine » Biopharma

Beam Therapeutics Inc. Announces $260 Million Common Stock Investment from Multiple Investors

CAMBRIDGE, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) — Beam Therapeutics Inc. (Nasdaq: BEAM) (the “Company”), a biotechnology company developing precision genetic medicines through base editing, today announced that...

AbSci Announces Acquisition of Deep Learning Company Denovium

LifeMine Therapeutics Announces $50 Million Series B Financing

Proceeds will enable advancement and acceleration of the Company’s transformative drug discovery programs derived from digital search of the fungal biosphere to discover and develop highly impactful precision medicines...

Indee Labs Announces Successful Early Access Program Launch

Charles River Laboratories Acquires Distributed Bio

Poseida Therapeutics added to NASDAQ Biotechnology Index

Gamida Cell Added to NASDAQ Biotechnology Index

Atomwise and FutuRx Launch A2i Therapeutics – A New Immuno-Oncology Company Funded By Leading Biopharma VCs and the Israeli Innovation Authority

AbCellera Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares

AbCellera Announces Pricing of Initial Public Offering

Sutro Biopharma Announces Closing of Upsized $144.9 Million Public Offering, including Full Exercise of the Underwriters’ Option to Purchase Additional Shares

AbCellera Expands Technology Stack with Acquisition of Trianni for $90 Million

Precigen Announces Dosing of First Patients with UltraCAR-T® Cells Manufactured Using Proprietary UltraPorator™ System in Ongoing PRGN-3005 and PRGN-3006 Phase 1 Clinical Trials

Can We Recreate Every Human Cell Type In The Body? This UK Startup Thinks So.

Locus Biosciences signs contract with CARB-X to advance $14 million precision medicine program to develop crPhage™ product targeting Klebsiella pneumoniae infections